Elevance Health, Inc. Revenue & Financials

Revenue grew from $138.4 billion in 2021 to $159.3 billion in 2024 — a $20.9 billion increase driven primarily by Medicaid enrollment growth, Medicare Advantage expansion, and premium rate increases across commercial lines. The growth is consistent but the margins are thin: net income reached $5.8 billion on $159.3 billion in revenue, a 3.6% net margin that reflects the capital-intensive, pass-through nature of managed care economics. The 2023 Medicare Advantage star ratings downgrade created real financial pressure. Star ratings determine bonus payments from the Centers for Medicare and Medicaid Services — lower stars mean lower payments, which compress the margin on a membership base that Elevance had spent years building. Recovering those ratings requires clinical quality improvements that take time and investment to demonstrate. The scrutiny over prior authorization and claims denials in 2024 represents a regulatory and reputational risk that is sector-wide but falls hardest on the largest operators. Elevance, as the dominant Blue Cross Blue Shield licensee, faces the most visibility. The political pressure to limit denial rates directly conflicts with the financial logic of use management. Revenue held nearly flat between 2022 and 2023 — $156.6 billion versus $156.6 billion — before resuming growth in 2024. That pause reflected the rate cycle dynamics of managed care more than any operational deterioration. The $115 billion market capitalization implies the market is pricing steady, regulated returns rather than high-growth returns.